Figure 3.
VSV-infected DCs mediate therapeutic tumor destruction. (a) Mice were challenged with 1 × 106 B16-OVA cells intravenously and immunized 10 days later with PBS, DC-VSV/MT, or DC-VSV/SIIN. Mice were killed 11 days after immunization (21 days after challenge), lungs were collected and tumour nodules were counted using a dissecting microscope (significantly greater tumor burden in PBS compared to DC-VSV/MT (**P < 0.001) and DC-VSV/SIIN (**P < 0.001) *P < 0.05, significant difference between DC-VSV/MT and DC-VSV/SIIN). (b) Mice were immunized with DCs treated LPS with or without SIINFEKL peptide pulsing, or infected with recombinant Ad carrying SIINFEKL (DC/Ad-SIIN) or no transgene (DC/Ad-BHG). Significant reduction compared to PBS, **P < 0.001. Bars represent means ± SEM from two independent experiments with 5 mice/group. DC, dendritic cell; LPS, lipopolysaccharide; OVA, ovalbumin; PBS, phosphate-buffered saline; VSV, vesicular stomatitis virus.